TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38315832
Drug: 3L chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3L chemotherapy with SCT after salvage chemotherapy (n=10)
Study: 38315832
Drug: 3L chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3L chemotherapy without SCT after salvage chemotherapy (n=50)
Study: 38315832
Drug: 3L cellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3L cellular immunotherapy after 2L axi-cel (n=8)
Study: 38315872
Drug: Single IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV dose of 1080 mg
Study: 38315872
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) dosing of 1080 mg on 3 consecutive days
Study: 38315872
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment with pegcetacoplan (IV or SC)
Study: 38315944
Drug: Trabectedin 1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin 1.3 mg/m²
Study: 38315945
Drug: Cinpanemab (human-derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinpanemab (human-derived monoclonal antibody) administered intravenously every 4 weeks for 52 weeks
Study: 38316055
Drug: Patient-specific treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-specific treatment planning using measured, homogeneous optical properties
Study: 38316133
Drug: Oral decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral decitabine 35 mg plus cedazuridine 100 mg on days 1-5 and venetoclax (400 mg) for 14 days
Study: 38316236
Drug: Intraoperative dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraoperative dexamethasone followed by a 6-day oral methylprednisolone taper course
Study: 38316588
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral dose of three strains of probiotics
Study: 38316601
Drug: Lean protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lean protein sources (e.g., chicken) replacing legumes in entrées.
Study: 38317178
Drug: 5% albumin
Normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% albumin (12 mL/kg)
Study: 38317178
Drug: 20% albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% albumin (3 mL/kg)
Study: 38317420
Drug: Subcutaneous blinatumomab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous blinatumomab
Study: 38318125
Drug: S48168 (ARM210)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S48168 (ARM210) 120 mg daily for 29 days
Study: 38318125
Drug: S48168 (ARM210)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S48168 (ARM210) 200 mg daily for 29 days
Study: 38318236
Drug: Efgartigimod (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efgartigimod (10 mg/kg infusion per week for 4 weeks)
Study: 38318270
Drug: Heparin (3000-7500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (3000-7500 U for vascular surgery, 27,500-40,000 U for cardiac surgery)
Study: 38318270
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (5000 U subcutaneously)
Study: 38318484
Drug: 0.01% menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% menthol solution
Study: 38318484
Drug: Placebo noncaloric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo noncaloric solution
Study: 38318773
Drug: Primary care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary care allied health treatment
Study: 38318773
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment plan including physical exercise
Study: 38319178
Drug: Molnupiravir 200
Normalized name: molnupiravir 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molnupiravir 200 mg, 400 mg, or 800 mg, twice daily for 5 days
Study: 38319178
Drug: Molnupiravir (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molnupiravir (all doses combined)
Study: 38319179
Drug: Molnupiravir (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molnupiravir (combined group of 200, 400, or 800 mg)
Study: 38319181
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy and education (12-week supervised)
Study: 38319181
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy and education
Study: 38319229
Drug: Heart failure
Normalized name: INVESTIGATIONAL CONGESTIVE HEART FAILURE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart failure treatment
Study: 38319239
Drug: Low-dose subcutaneous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose subcutaneous aldesleukin (recombinant IL-2), 0.3 to 3.0 × 106 IU daily for 5 consecutive days (part A)
Study: 38319239
Drug: Low-dose subcutaneous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose subcutaneous aldesleukin (recombinant IL-2), 1.5 and 2.5 × 106 IU daily for 5 consecutive days (part B)
Study: 38319241
Drug: Zilovertamab vedotin
Normalized name: Zilovertamab vedotin
DrugBank: Zilovertamab vedotin (DB18457)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zilovertamab vedotin (ZV) at doses of 0.5, 1.0, 1.5, 2.25, and 2.5 mg/kg every 3 weeks until cancer progression or unacceptable toxicity.
Study: 38319253
Drug: High-dose adeno-associated
Normalized name: ADENO-ASSOCIATED VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose adeno-associated viral vector serotype 8 expressing ARSB
Study: 38319253
Drug: Low and
Normalized name: ZINC OXIDE 88 mg in 1 mL TOPICAL LOTION [Ciele Glow and Protect]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low and intermediate dose cohorts of adeno-associated viral vector serotype 8 expressing ARSB
Study: 38319689
Drug: AMH cutoff
Normalized name: Sodium Fluoride 0.007 mg in 35 mL ORAL SPRAY [AMHEALER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMH cutoff of 3.2 ng/mL for the Elecsys AMH Plus or Elecsys AMH assays (Roche)
Study: 38319800
Drug: Abiraterone (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abiraterone (1000 mg once daily) plus olaparib (300 mg twice daily)
Study: 38319800
Drug: Abiraterone (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abiraterone (1000 mg once daily) plus placebo
Study: 38319804
Drug: Infliximab discontinuation
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab discontinuation (placebo)
Study: 38319812
Drug: Sabizabulin (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sabizabulin (9 mg orally daily for up to 21 days)
Study: 38319837
Drug: Decitabine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decitabine (20 mg/m2 daily on days 1 to 3 every 28-day cycle)
Study: 38319837
Drug: Azacitidine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azacitidine (75 mg/m2 daily on days 1 to 3 every 28-day cycle)
Study: 38319837
Drug: Decitabine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decitabine (20 mg/m2 daily)
Study: 38319837
Drug: Azacitidine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azacitidine (75 mg/m2 daily)
Study: 38319852
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg intravenously every 3 weeks for a total of 18 doses)
Study: 38319892
Drug: STRIDE (tremelimumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: STRIDE (tremelimumab 300 mg, one dose plus durvalumab 1500 mg every 4 weeks)
Study: 38319892
Drug: Durvalumab (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (1500 mg every 4 weeks)
Study: 38319910
Drug: Nutritional status
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional status assessment using bioelectrical impedance analysis (BIA) throughout multimodal treatment.
Study: 38320023
Drug: Nivolumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab + Relatlimab (480 mg + 160 mg fixed-dose combination)
Study: 38320023
Drug: Nivolumab (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (480 mg alone)
Study: 38320033
Drug: Low-dose low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose low-molecular-weight heparin thromboprophylaxis
Study: 38320033
Drug: Intermediate-dose low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-dose low-molecular-weight heparin thromboprophylaxis
Study: 38320033
Drug: Low-dose plus
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose plus aspirin
Study: 38320033
Drug: Therapeutic-dose anticoagulation
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic-dose anticoagulation
Study: 38320088
Drug: Females, BMI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Females, BMI ≥23 kg/m2, No.12 lymph node dissection, adjuvant chemotherapy
Study: 38320097
Drug: Increased water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased water intake (exact dosage and duration not specified)
Study: 38320126
Drug: Ropeginterferon alfa-2b
Normalized name: Ropeginterferon alfa-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ropeginterferon alfa-2b (ropeg; 100 μg every 2 weeks)
Study: 38320126
Drug: Phlebotomy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phlebotomy only (standard therapy)
Study: 38320129
Drug: Avapritinib 25
Normalized name: avapritinib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avapritinib 25 mg once daily
Study: 38320142
Drug: Enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (40 mg/day for 6 to 14 days)
Study: 38320144
Drug: Nalbuphine extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine extended-release tablets (NAL ER) started at a dose of 27 mg once daily, titrated up to 162 mg twice daily at day 16.
Study: 38320144
Drug: Nalbuphine extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine extended-release tablets (NAL ER)
Study: 38320155
Drug: 4-month regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-month regimen of rifampicin at 1800 mg/d (SR2)
Study: 38320155
Drug: 4-month regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-month regimen of rifampicin at 1200 mg/d (SR1)
Study: 38320181
Drug: Tezepelumab (210
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezepelumab (210 mg every 4 weeks subcutaneously for at least 28 weeks)
Study: 38320179
Drug: Vemurafenib 960
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vemurafenib 960 mg twice daily for four cycles plus obinutuzumab administered in cycles 2 to 4
Study: 38320240
Drug: Interfascial injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interfascial injection of 10 mL of 10% dextrose water
Study: 38320240
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection of 0.5 mL of 10% dextrose water
Study: 38320431
Drug: Peposertib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peposertib 200 mg b.i.d. plus avelumab
Study: 38320431
Drug: Peposertib 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peposertib 250 mg q.d. plus avelumab and radiotherapy
Study: 38320431
Drug: Recommended phase
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended phase II dose (RP2D) and maximum tolerated dose (MTD)
Study: 38320431
Drug: Pharmacokinetics of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetics of peposertib
Study: 38320464
Drug: Uncontrolled glycemia
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uncontrolled glycemia (glucose levels ≥175 mg/dL)
Study: 38320464
Drug: Controlled glycemia
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled glycemia (glucose levels <175 mg/dL)
Study: 38320488
Drug: Two-dose 9vHPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose 9vHPV vaccine (0 and 6 months)
Study: 38320488
Drug: Three-dose 9vHPV
Normalized name: THREE-LOBE SAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose 9vHPV vaccine (0, 2, and 6 months)
Study: 38320488
Drug: Two-dose 9vHPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose 9vHPV vaccine
Study: 38320488
Drug: Three-dose 9vHPV
Normalized name: THREE-LOBE SAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-dose 9vHPV vaccine
Study: 38320498
Drug: ARO-APOC3 10
Normalized name: ARO-APOC3
DrugBank: ARO-APOC3 (DB17625)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARO-APOC3 10 mg
Study: 38320498
Drug: ARO-APOC3 25
Normalized name: ARO-APOC3
DrugBank: ARO-APOC3 (DB17625)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARO-APOC3 25 mg
Study: 38320498
Drug: ARO-APOC3 50
Normalized name: ARO-APOC3
DrugBank: ARO-APOC3 (DB17625)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARO-APOC3 50 mg
Study: 38320498
Drug: ARO-APOC3 100
Normalized name: ARO-APOC3
DrugBank: ARO-APOC3 (DB17625)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARO-APOC3 100 mg
Study: 38320500
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of dapagliflozin
Study: 38320500
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of saxagliptin
Study: 38320501
Drug: Combination (enzalutamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (enzalutamide plus leuprolide)
Study: 38320501
Drug: Monotherapy (enzalutamide)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (enzalutamide)
Study: 38320513
Drug: ODM-208 5
Normalized name: ODM-203
DrugBank: ODM-203 (DB16843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ODM-208 5 mg twice daily with glucocorticoid/mineralocorticoid replacement
Study: 38320513
Drug: ODM-208 5
Normalized name: ODM-203
DrugBank: ODM-203 (DB16843)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ODM-208 5 mg twice daily
Study: 38320524
Drug: Difelikefalin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Difelikefalin 0.5 μg/kg intravenously three times per week for 6 weeks
Study: 38320840
Drug: Education about
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education about genomic medicine provided to neonatal providers
Study: 38321023
Drug: agenT-797 (donor-unrestricted
Approvals — FDA: no, EMA: no, PMDA: no
Description: agenT-797 (donor-unrestricted allogeneic ex vivo expanded iNKT cell therapy)
Study: 38321218
Drug: OMO-103 (6.48
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMO-103 (6.48 mg/kg, DL5)
Study: 38321220
Drug: UBX1325 (foselutoclax),
Approvals — FDA: no, EMA: no, PMDA: no
Description: UBX1325 (foselutoclax), a senolytic small-molecule inhibitor of BCL-xL
Study: 38321617
Drug: Behaviorally-based treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behaviorally-based treatments
Study: 38322553
Drug: AllerPops prebiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: AllerPops prebiotic supplements
Study: 38322862
Drug: Esketamine infusion
Normalized name: esketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine infusion (0.75 mcg/ml) combined with sufentanil (1.5 mcg/ml) for 24 hours
Study: 38322862
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (sufentanil 1.5 mcg/ml alone)
Study: 38322981
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol (CBD) 25 mg 3 times/day if <80 kg and 50 mg 3 times/day if >80 kg for 14 days
Study: 38323173
Drug: Intravenous fosaprepitant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fosaprepitant (arm A)
Study: 38323173
Drug: Oral aprepitant
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral aprepitant (arm B)
Study: 38323513
Drug: Personalized amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized amlodipine dose titration (novel doses: 1, 2, 3, 4, 6, 7, 8, 9 mg; standard doses: 5 and 10 mg) over 14 weeks.
Study: 38323949
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy-based Creating Opportunities for Personal Empowerment program
Study: 38324085
Drug: Navarixin 30
Normalized name: Navarixin
DrugBank: Navarixin (DB11711)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navarixin 30 mg plus pembrolizumab
Study: 38324085
Drug: Navarixin 100
Normalized name: Navarixin
DrugBank: Navarixin (DB11711)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navarixin 100 mg plus pembrolizumab
Study: 38324085
Drug: Navarixin 30
Normalized name: Navarixin
DrugBank: Navarixin (DB11711)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navarixin 30 mg
Study: 38324085
Drug: Navarixin 100
Normalized name: Navarixin
DrugBank: Navarixin (DB11711)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navarixin 100 mg
Study: 38324280
Drug: β-blocker withdrawal
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-blocker withdrawal
Study: 38324367
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy-based treatment app (Spark)
Study: 38324415
Drug: Apixaban, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban, 5 mg or 2.5 mg, twice daily (n=507)
Study: 38324415
Drug: Aspirin, 81
Normalized name: Aspirin, 81 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin, 81 mg, once daily (n=508)
Study: 38324484
Drug: JNJ-77242113 25
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-77242113 25 mg once daily
Study: 38324484
Drug: JNJ-77242113 25
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-77242113 25 mg twice daily
Study: 38324484
Drug: JNJ-77242113 50
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-77242113 50 mg once daily
Study: 38324484
Drug: JNJ-77242113 100
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-77242113 100 mg once daily
Study: 38324484
Drug: JNJ-77242113 100
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-77242113 100 mg twice daily
Study: 38324741
Drug: Crenolanib plus
Normalized name: Crenolanib
DrugBank: Crenolanib (DB11832)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crenolanib plus intensive chemotherapy
Study: 38325290
Drug: Penicillin Skin
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin Skin Testing (PST) followed by amoxicillin 250 mg challenge
Study: 38325290
Drug: Graded Oral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded Oral Challenge (GOC) with amoxicillin 25 mg followed by 250 mg
Study: 38325328
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg intravenously every 3 weeks in conjunction with glass yttrium-90 (Y90) radioembolization TheraSphere
Study: 38325765
Drug: Protein intake
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein intake of 1.08 g⋅kg
Study: 38325988
Drug: Roux-en-Y gastric
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roux-en-Y gastric bypass (RYGB) combined with medical therapy (MT)
Study: 38326352
Drug: Escitalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (20 mg daily)
Study: 38326734
Drug: High-Intensity Resistance
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Resistance Training (HIRT) for 16 months, twice weekly
Study: 38326920
Drug: Human serum
Normalized name: Human serum albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human serum albumin 20% 100 mL over 15 min
Study: 38326920
Drug: Saline 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 500 mL
Study: 38327730
Drug: Medication-free treatment
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-free treatment
Study: 38328552
Drug: Part 1
Normalized name: INSULIN,ASPART 100 UNIT/ML 3ML CART
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1 therapy for 6 weeks followed by full therapy
Study: 38328709
Drug: inetetamab (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: inetetamab (loading dose of 8 mg/kg and subsequent doses of 6 mg/kg intravenously once every 3 weeks), pyrotinib (400 mg orally once daily), and vinorelbine (60 mg/m2 weekly)
Study: 38328709
Drug: inetetamab, pyrotinib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: inetetamab, pyrotinib, and oral vinorelbine
Study: 38329148
Drug: Tenecteplase (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenecteplase (0.25 mg/kg, up to 25 mg)
Study: 38329153
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for 7 weeks
Study: 38329404
Drug: Short-time cardiac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-time cardiac MRI in breast cancer participants undergoing chemotherapy
Study: 38329404
Drug: Short-time cardiac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-time cardiac MRI in breast cancer participants undergoing immediate chemotherapy
Study: 38329404
Drug: Short-time cardiac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-time cardiac MRI in breast cancer participants undergoing remote chemotherapy
Study: 38329507
Drug: Adjuvant (super-)selective
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant (super-)selective infusion of holmium-166 microspheres after radiofrequency ablation
Study: 38329646
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg ocedurenone administered orally
Study: 38329716
Drug: Futibatinib 20
Normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Futibatinib 20 mg once daily